Company intelligence / Profile preview

Navipharm

Ownership: Private
Development stage: Other

Overview

Navipharm has multiple small molecule drug candidates in Phase 1 clinical trials targeting nervous system and cardiovascular diseases. Its Korean division has developed clinically tested duo-strain probiotics with commercial launches addressing allergic rhinitis, sleep/anxiety, liver health, and menopause-related symptoms.

Therapeutic areas: ImmunologyPsychiatryGastroenterologyCardiovascularNeurologyWomen's Health
Modalities: Small moleculeProbiotic-based therapy
Industry: Biotech

Drug pipeline

11 assets

NVP-1705

10 more assets in the full pipeline.

Request access →

Partnerships

No major global pharmaceutical partnerships publicly listed; the company engages in licensing deals and project management collaborations with clients globally.

Beyond the preview

Go deeper on Navipharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navipharm.

Explore the full profile